Journal of the American Pharmacists Association : JAPhA
-
J Am Pharm Assoc (2003) · May 2002
Drotrecogin alfa (activated) approved for treatment of severe sepsis.
Drotrecogin alfa (activated) is a recombinant form of human activated protein C that has been shown to reduce mortality in severely septic patients with a high risk of death. Given the complexity of the inclusion and exclusion criteria, the stability and unique duration of infusion, and the cost of treatment, therapy with this agent should be carefully considered to ensure its appropriate use.